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Abstract  Idiopathic  pulmonary  ﬁbrosis  (IPF)  is  a  progressive  and  fatal  lung  disease  that  up
to now  has  been  associated  with  a  poor  prognosis.  However,  the  results  of  the  INPULSIS  and
ASCEND trials  and  the  approval  of  nintedanib  and  pirfenidone  have  marked  the  beginning  of
a new  era  for  IPF  patients.  Questions  remain,  however.  Should  these  drugs  be  used  earlier?disease;
Nintedanib;
Pirfenidone
What effect  will  they  have  on  more  severe  disease?  Will  their  effects  last  beyond  the  trial
period?  This  manuscript  is  the  outcome  of  a  multidisciplinary  meeting  between  pulmonology,
radiology,  and  pathology  clinicians  on  the  use  of  antiﬁbrotic  agents  in  IPF.  In  our  opinion,  the
existing data  show  that  pirfenidone  and  nintedanib  slow  functional  decline  in  early  stages∗ Corresponding author.
E-mail address: carlos.crobalo@gmail.com (C. Robalo-Cordeiro).
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of  disease.  These  drugs  also  appear  to  result  in  therapeutic  beneﬁts  when  administered  to
patients with  advanced  disease  at  diagnosis  and  maintain  effective  over  time.  The  data  also
suggest that  continuing  antiﬁbrotic  therapy  after  disease  progression  may  confer  beneﬁts,  but
more evidence  is  needed.  Early  diagnosis  and  treatment  are  crucial  for  reducing  functional
decline, slowing  disease  progression,  and  improving  quality  of  life.
© 2017  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an






















































































decline  in  mean  6-min  walk  distance  (6MWD)  than  patientsntroduction
diopathic  pulmonary  ﬁbrosis  (IPF)  is  a  progressive  and
eadly  disease  with  a  mean  survival  of  3--5  years  from  the
ime  of  diagnosis.  It  is  more  common  in  men,  smokers,  and
eople  over  50  years  old.1,2 The  condition  is  characterized
y  dyspnea  on  exertion,  non-productive  cough,  crackles  on
uscultation,  and  digital  clubbing.  It  is  diagnosed  using  a
peciﬁc  combination  of  radiologic  and/or  histopathological
atterns  of  usual  interstitial  pneumonia  (UIP)  and  exclusion
f  other  known  causes  of  UIP.1,3 General  physicians  must  be
ble  to  recognize  the  symptoms  of  IPF  to  ensure  the  timely
eferral  of  suspected  cases,  and  it  is  essential  that  these
re  then  evaluated  by  a  multidisciplinary  team  with  expe-
ience  in  interstitial  lung  diseases  to  ensure  an  accurate
iagnosis.1,4--8
This  manuscript  is  the  outcome  of  a  multidisciplinary
eeting  in  which  pulmonology,  radiology,  and  pathology
linicians  came  together  to  debate  topics  related  to  the  use
f  antiﬁbrotic  drugs  in  the  treatment  of  IPF.
PF treatment: a recent (r)evolution
PF  was  initially  considered  to  be  a  chronic  inﬂamma-
ory  process  and  therefore  early  treatment  strategies
imed  to  eliminate  or  suppress  the  inﬂammatory  com-
onent.  In  2000,  the  ﬁrst  international  guidelines  on
PF  diagnosis  and  treatment  recommended  corticosteroids
nd  immunosuppressive/cytotoxic  agents  (azathioprine  or
yclophosphamide)  as  ‘‘standard  treatment’’,  despite  the
eak  evidence  available.9 This  targeting  of  inﬂammatory
athways,  however,  produced  disappointing  results.4,10--12
Understanding  of  IPF  pathobiology  improved  signiﬁcantly
ollowing  the  publication  of  the  2000  IPF  guidelines  and  it
as  proposed  that  the  disease  might  be  the  result  of  an  aber-
ant  healing  response  to  recurrent  alveolar  epithelial  cell
njury.13,14 Guidelines  published  in  2011  concluded  there  was
nsufﬁcient  evidence  to  continue  to  recommend  corticos-
eroid  and  immunomodulatory  agents  as  standard  therapy
or  IPF.15 The  results  of  the  IFIGENIA  study,  a  double-blind
linical  trial  designed  to  investigate  the  potential  role  of
ntioxidant  pathways  in  IPF,  were  published  in  2005.  The
rial,  which  compared  prednisolone  plus  azathioprine  with
rednisolone  plus  azathioprine  plus  N-acetylcysteine  (NAC),
howed  a  signiﬁcantly  reduced  decline  in  forced  vital  capac-
ty  (FVC)  (p  =  0.02)  and  diffusion  capacity  of  the  lung  for
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eeks.16 Although  the  trial  had  some  methodological  pit-
alls,  this  triple  therapy  became  the  new  standard  treatment
or  IPF.
Around  the  same  time,  pirfenidone,  an  orally  bioavailable
ynthetic  compound  with  antiﬁbrotic,  anti-inﬂammatory,
nd  antioxidant  effects,  was  being  studied  in  clinical  tri-
ls  in  Japan.17,18 Although  the  exact  mechanism  of  action
f  pirfenidone  in  IPF  is  not  yet  completely  understood,
ts  anti-inﬂammatory  effects  are  believed  to  result  from
he  suppression  of  tumor  necrosis  factor    (TNF-), inter-
eukin  (IL)-6,  IL-12,  and  IL-8,19 while  its  anti-ﬁbrotic  effect
s  thought  to  result  primarily  from  inhibition  of  expres-
ion  of  transforming  growth  factor  beta  --  a  proﬁbrotic
ytokine  -- although  other  pathways  have  been  suggested.20
he  ﬁrst  Japanese  trial,  a  phase  II,  multicenter,  random-
zed,  double-blind  trial,  showed  no  signiﬁcant  treatment
ffect  for  pirfenidone  on  the  primary  endpoint,  which  was
 change  from  baseline  in  the  lowest  oxygen  saturation  by
ulse  oximetry  [SpO2] during  a  6-min  exercise  test.  It  did,
owever,  show  that  the  high-dose  treatment  (1800  mg/day)
ad  a  positive  effect  in  reducing  VC  decline,  a  secondary
ndpoint,  at  9  months.17 In  addition,  acute  exacerbations
ere  only  observed  in  the  placebo  group  during  the  same
eriod.  A  subsequent  multicenter,  randomized,  double-blind
hase  III  clinical  trial  of  275  IPF  patients  randomly  assigned
o  pirfenidone  1800  mg/day,  pirfenidone  1200  mg/day,  or
lacebo  for  52  weeks,  showed  a  signiﬁcantly  slower  decline
n  FVC  and  better  progression-free  survival  in  the  two  pir-
enidone  groups  compared  with  placebo.18 Based  on  the
esults  of  these  two  studies,  pirfenidone  was  approved  for
PF  treatment  by  the  Japanese  authorities  in  2008.
Meanwhile,  pirfenidone  was  also  being  studied  in  Europe
nd  in  the  United  States  of  America  (USA)  in  the  CAPAC-
TY  trials.21 The  placebo-controlled  phase  III  trials,  CAPACITY
04  and  006,  showed  contradictory  results,  and  the  primary
ndpoint  of  a  signiﬁcant  reduction  in  FVC  decline  at  week
2  was  only  met  in  study  004.  However,  the  pooled  anal-
sis  revealed  a  signiﬁcant  reduction  in  the  mean  decline
f  absolute  and  percent  predicted  FVC  and  the  number
f  patients  with  an  FVC  decline  ≥10%  at  week  72  in  the
403  mg/day  pirfenidone  group.21 In  relation  to  the  second-
ry  endpoints,  the  patients  in  the  2403  mg/day  group  also
ad  longer  progression-free  survival  and  a  lower  rate  ofn  the  placebo  group.21 The  results  of  this  pooled  analysis  led
o  the  approval  of  pirfenidone  for  IPF  treatment  by  the  Euro-
ean  Medicines  Agency  (EMA)  in  2011,  although  they  were
icalKey.com by Elsevier on October 12, 2017.
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not  sufﬁcient  to  convince  the  US  Food  and  Drug  Administra-
tion  (FDA).
Despite  the  approval  of  pirfenidone  in  Japan  and  Europe,
the  triple  therapy  persisted  as  the  treatment  regimen  of
choice  in  many  countries  until  the  results  of  the  PANTHER
study  were  published.11 The  PANTHER  study  was  a  random-
ized  clinical  trial  with  three  arms:  a  triple  therapy  arm,
an  NAC  arm,  and  a  placebo  arm.  The  triple  therapy  arm
was  stopped  after  a  mean  follow-up  of  32  weeks  because  of
higher  mortality  and  hospitalization  rates  than  in  the  other
two  groups.11
Despite  some  initial  controversy,  this  event  marked  the
end  of  triple  therapy.  Moreover,  on  completion  of  the  PAN-
THER  study  in  2014,  no  signiﬁcant  differences  were  detected
between  NAC  and  placebo  for  changes  in  FVC  (primary  end-
point)  or  for  death  rates  or  frequency  of  acute  exacerbations
(secondary  endpoints).22 Recent  publications  describing  a
therapeutic  effect  for  NAC  in  a  subgroup  of  IPF  patients
expressing  the  TOLLIP  gene  polymorphism  rs375092023
and  a  potential  beneﬁt  of  inhaled  acetylcysteine,24 have
rekindled  the  discussion  about  the  potential  therapeutic
role  of  NAC  and  antioxidants  as  a  therapeutic  group  in
IPF.
After  the  evaluation  of  the  CAPACITY  trials,19 the  ASCEND
trial,  which  included  555  patients  from  the  USA,  Europe,
and  Australia  randomly  assigned  to  receive  2403  mg/day
of  pirfenidone  or  placebo  for  52  weeks  showed  that  the
treatment  group  had  a  signiﬁcantly  reduced  absolute  FVC
decline,  fewer  patients  with  an  FVC  decline  ≥10%,  better
progression-free  survival  (deﬁned  as  the  time  to  occurrence
of  a  conﬁrmed  absolute  decrease  of  ≥10  percentage  points
in  percent  predicted  FVC,  a  conﬁrmed  decrease  of  ≥50  m  in
the  6MWD,  or  death),  and  fewer  patients  with  a  decrease
of  ≥50  m  in  the  6MWD.25 Moreover,  pooled  data  from  the
CAPACITY  and  ASCEND  trials  evidenced  a  reduction  in  both
all-cause  and  IPF-related  mortality  after  one  year.25 These
results  further  supported  the  efﬁcacy  of  pirfenidone  in  IPF
and  led  to  FDA  approval  in  2014.
In  the  same  year,  nintedanib  also  received  FDA  approval
after  the  INPULSIS  trials.26 Nintedanib  is  a  small  molecule
tyrosine  kinase  inhibitor  that  targets  the  receptors  of
platelet-derived  growth  factor,  ﬁbroblast  growth  factor,
and  vascular  endothelial  growth  factor.  Blockage  of  these
receptors  may  inhibit  downstream  signaling  cascades  of
ﬁbroblasts  and  myoﬁbroblasts,  attenuating  the  development
of  aberrant  ﬁbrosis.27
In  the  phase  II  nintedanib  trial  TOMORROW,  which
included  432  IPF  patients  randomized  to  one  of  four  doses
of  nintedanib  (50  mg  od,  50  mg  bid,  100  mg  bid,  and  150  mg
bid)  or  placebo,  a  signiﬁcant  reduction  in  FVC  decline  after
52  weeks  was  seen  in  the  150  mg  bid  group  compared  with
placebo.28 This  subgroup  of  patients  also  had  signiﬁcantly
fewer  acute  exacerbations  and  a  smaller  mean  decrease  in
the  St.  George’s  Respiratory  Questionnaire  score.  Two  sub-
sequent  large  phase  III  trials,  INPULSIS  1  and  2,  comparing
150  mg  bid  of  nintedanib  with  placebo  in  1066  patients,
showed  a  reduction  in  the  annual  rate  of  decline  in  abso-
lute  and  percent  predicted  FVC  (primary  endpoint)  and
an  increase  in  time  to  the  ﬁrst  acute  exacerbation  for
nintedanib.26 With  these  results,  the  EMA  few  months  after
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A  new  era  emerged  for  patients  with  IPF  following
he  INPULSIS26 and  ASCEND25 trials  and  the  approval  of
intedanib  and  pirfenidone.29 The  two  drugs  were  identiﬁed
n  national  and  international  guidelines  on  the  diagnosis  and
reatment  of  IPF  as  being  efﬁcacious  in  slowing  functional
ecline  and  disease  progression  in  IPF  patients.1,30--33
The  nintedanib  and  pirfenidone  trials  showed  similar
fﬁcacy  results  but  raised  logical  questions  related  to
ow  the  drugs  would  perform  in  the  real  world,  outside
he  restrictions  of  the  trials.  The  inclusion  criteria  varied
omewhat  between  the  INPULSIS  (nintedanib)  and  ASCEND
pirfenidone)  trials.  The  pirfenidone  trials21,25 included
atients  with  percent  predicted  FVC  50--90%,  predicted
LCO  30--90%  and  high-resolution  computed  tomography
HRCT)  images  indicating  either  deﬁnite  or  possible  UIP,
owever  with  conﬁrmation  by  surgical  lung  biopsy.  The
intedanib  trials,26,28 by  contrast,  included  patients  with
ercent  predicted  FVC  >50%,  predicted  DLCO  30--79%,  and
RCT  images  indicating  deﬁnite  or  possible  UIP.  Following
ublication  of  the  trials,  several  post-marketing  surveillance
tudies  and  subgroup  analyses  investigating  effects  accord-
ng  to  age  or  stage  of  disease  were  undertaken  in  order  to
nswer  several  questions:  If  these  drugs  are  efﬁcacious  in
lowing  the  progression  of  IPF,  should  they  be  used  earlier?
ow  will  they  behave  in  patients  with  more  severe  disease?
ill  their  effects  extend  beyond  the  trial  period?29,34
hen should IPF treatment be started?
he  most  controversial  question  currently  surrounding  IPF
reatment  is  probably  when  it  should  be  started.  We  know
hat  IPF  is  a  progressive  disease  and  that  both  pirfenidone
nd  nintedanib  slow  functional  decline.  However,  some
atients  remain  stable  for  several  months  and  it  has  been
rgued  that  in  a  stable  patient  with  mild  disease,  treatment
hould  be  postponed  until  functional  decline  begins.  Nev-
rtheless,  it  is  impossible  to  predict  the  rate  or  severity  of
isease  progression  in  each  patient  or  to  know  when  they
ill  experience  an  acute  exacerbation.  Moreover,  we  cannot
e  sure  that  deleterious  subclinical  changes  are  not  tak-
ng  place  in  patients  without  signs  of  signiﬁcant  functional
eterioration.
In  a  recent  post  hoc  subgroup  analysis  of  pooled  data
rom  the  INPULSIS  trials,  Kolb  et  al.  described  similar  rates
f  FVC  decline  in  nintedanib-treated  patients  with  percent
redicted  FVC  >90%  and  ≤90%  (Fig.  1).35 Other  pre-speciﬁed
ubgroup  analyses  have  shown  similar  results,  with  a  con-
istent  effect  observed  for  nintedanib  in  patients  with  FVC
70%  and  >70%.36
In  a  post  hoc  analysis  of  pooled  data  from  the  CAPACITY
nd  ASCEND  trials,  Albera  et  al.37 showed  similar  clini-
ally  signiﬁcant  disease  progression  (decline  in  FVC,  6MWD,
nd  dyspnea  measured  by  the  University  of  California,  San
iego  Shortness  of  Breath  Questionnaire)  at  12  months  in
irfenidone-treated  patients  with  more  preserved  lung  func-
ion  (FVC  ≥80%  or  GAP  stage  I)  and  less  preserved  lung
unction  (FVC  <80%  or  GAP  stage  II--III)  at  baseline.  The  GAP
ndex  is  a  multidimensional  IPF  staging  model  that  takes  into
ccount  gender  (G),  age  (A),  and  2  lung  physiology  varia-
les  (P)  (FVC  and  DLCO);  it  distinguishes  between  stages
,  II,  and  III.38 The  magnitude  of  the  pirfenidone  treatment
linicalKey.com by Elsevier on October 12, 2017.
017. Elsevier Inc. All rights reserved.
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Figure  1  Evidence  that  favors  the  use  of  antiﬁbrotics  in  IPF  
irfenidone (adapted  from  37).
ffect  was  comparable  between  the  subgroups,  regardless
f  whether  lung  function  was  classiﬁed  as  using  FVC  or  the
AP  model  (Fig.  1).37
The  above  data  suggest  that  patients  diagnosed  in  early
tages  of  disease  experience  signiﬁcant  functional  deteri-
ration  and  that  both  nintedanib  and  pirfenidone  have  a
ositive  effect  in  terms  of  slowing  progression  in  these  early
tages  (Fig.  2),  clearly  supporting  the  recommendation  to
nitiate  treatment  immediately  after  IPF  diagnosis  and  high-
ighting  the  importance  of  prompt  diagnosis.
evere disease
ercent  predicted  FVC  <50%  is  usually  associated  with  severe
isease.  As  stated  earlier,  this  was  an  exclusion  criterion  in
oth  the  pirfenidone  and  nintedanib  trials.21,25,26,28 Infor-
ation  about  the  potential  effects  of  antiﬁbrotic  agents
n  patients  with  severe  disease  is  thus  scarce,  and  overall,
he  treatment  indications  outlined  by  the  health  authorities
xclude  patients  with  this  grade  of  functional  impairment.
Some  interesting  data  in  this  respect,  however,  have
merged  from  post-marketing  surveillance  studies.  In
he  open-label  INPULSIS-ON  extension  trial,  patients  who
tarted  treatment  with  nintedanib  150  mg  bid  with  per-
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ntiﬁbrotic  use  in  different  IPF  patient  subgroups.
ean  change  in  FVC  from  baseline  to  week  48  as  those  with
VC  >50%  at  baseline  (−62.3  mL  vs.  −87.9  mL),39 suggest-
ng  that  nintedanib  may  have  a  similar  therapeutic  effect  in
dvanced  forms  of  the  disease.
In  a  real-life  retrospective  study  of  pirfenidone  in  sev-
ral  Italian  interstitial  lung  disease  centers,  Harari  et  al.40
icalKey.com by Elsevier on October 12, 2017.






















































tIdiopathic  pulmonary  ﬁbrosis  in  the  era  of  antiﬁbrotic  thera
evaluated  128  IPF  patients  stratiﬁed  according  to  FVC  and
GAP  stage,  and  reported  a  greater  reduction  in  decline  in
percent  predicted  FVC  in  patients  with  moderate  to  severe
disease.
In  Japan,  a  retrospective  evaluation  of  1371  patients  who
began  pirfenidone  in  the  ﬁrst  year  after  its  approval  for
IPF  treatment  detected  functional  and  symptomatic  stabi-
lization,  regardless  of  degree  of  functional  impairment.41
Two-thirds  of  the  patients  were  considered  to  have  advanced
disease  (stage  III--IV,  according  to  a  four-stage  Japanese  IPF
staging  model  based  on  partial  pressure  of  arterial  oxygen
at  rest  and  SpO2 during  the  6  MW  test).41
At  the  recent  2016  European  Respiratory  Congress,  Costa-
bel  and  colleagues42 reported  on  the  results  of  a  comparison
of  54  patients  with  percent  predicted  FVC  ≤50%  with  530
patients  with  FVC  >50%  in  the  RECAP  trial,  which  was  an
extension  of  the  CAPACITY  trials.  Although  a  higher  treat-
ment  discontinuation  rate  was  observed  in  the  subgroup
with  more  advanced  disease,  long-term  treatment  with  pir-
fenidone  resulted  in  a  similar  rate  of  FVC  decline  in  both
groups.
Despite  the  relatively  small  number  of  patients,  the
above  data  suggest  that  both  nintedanib  and  pirfenidone
have  a  positive  effect  in  patients  who  have  advanced  disease
at  diagnosis  (Fig.  2).
Is the treatment effect maintained after 52
weeks?
Another  question  that  post-marketing  surveillance  studies
and  extension  trials  such  as  RECAP43 and  INPULSIS-ON44,45
have  attempted  to  answer  is  whether  or  not  the  positive
effect  observed  for  nintedanib  and  pirfenidone  in  terms  of
slowing  FVC  decline  is  maintained  after  52  weeks.
In  2014,  Valeyre  et  al.46 published  the  results  of  a  long-
term  safety  assessment  of  patients  treated  with  pirfenidone
in  the  CAPACITY  trials.  Although  safety  was  the  primary  focus
of  the  study,  the  authors  demonstrated  that  treatment  with
pirfenidone  for  up  to  7.7  years  (median,  2.6  years;  range,  1
week--7.7  years)  was  not  only  well  tolerated  but  also  showed
a  persistent  positive  therapeutic  effect.46
More  recently,  in  an  oral  communication  at  the  2016
ERS  Congress  (London,  3--9  September  2016),  Noble  et  al.47
presented  data  from  the  RECAP  extension  study  on  the  long-
term  effects  of  pirfenidone  on  percent  predicted  FVC  and
showed  that  the  drug  maintained  its  effect  over  more  than
3  years.
Finally,  in  a  recent  presentation  of  results  from  the
INPULSIS-ON  extension  study,  Crestani  showed  that  FVC
decline  was  similar  to  that  observed  in  the  original  INPUL-
SIS  trials,  suggesting  that  like  pirfenidone,  nintedanib  also
maintained  its  effect  for  over  3  years.44,45
What should be done once disease progression
is conﬁrmed?Disease  progression  in  IPF  is  deﬁned  as  a  sustained  decline  of
more  than  10%  in  FVC  and/or  of  15%  in  DLCO.  Lung  function
is  usually  evaluated  every  6  months  following  initiation  of
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he  treating  physician(s)  can  choose  to  suspend  the  drug
nd  administer  palliative  care  only;  suspend  the  drug  and
witch  to  an  alternative  therapy;  add  an  alternative  therapy;
r  continue  the  drug  despite  the  functional  decline.  There
s  insufﬁcient  evidence,  however,  to  support  any  of  these
ptions.  In  May  2016,  Nathan  et  al.48 published  the  results  of
 pooled  analysis  of  patients  from  the  CAPACITY  and  ASCEND
rials  showing  that  in  the  subgroup  of  patients  who  experi-
nced  a  functional  decline  in  FVC  >10%  after  6  months,  those
ho  continued  to  receive  pirfenidone  had  a  lower  risk  of
ubsequent  FVC  decline  or  death.  These  results  suggest  that
aintaining  antiﬁbrotic  therapy  may  confer  beneﬁts  even
fter  disease  progression  is  conﬁrmed.
Bonella  et  al., 49 in  a  German  multicenter  obser-
ational  study  of  nintedanib  in  IPF,  reported  that  a
ubgroup  of  patients  who  had  shown  disease  progression
nder  pirfenidone,  achieved  clinical  and  functional  stabil-
ty  when  switched  to  nintedanib.  A  combination  regimen
f  pirfenidone  and  nintedanib  has  also  been  proposed,
s  theoretically  it  would  allow  synergistic  activity  in
ifferent  ﬁbrotic  pathways.  One  safety  and  pharmacokine-
ics  study  reported  acceptable  tolerability  for  nintedanib
dministered  alone  or  with  pirfenidone  and  also  showed
hat  nintedanib  bioavailability  may  decrease  with  the  co-
dministration  of  pirfenidone.50 Despite  these  ﬁndings,
ore  data  and  studies  are  needed  to  guide  treatment  strat-
gies  in  patients  with  disease  progression.
hat is the impact of adverse events induced
y nintedanib or pirfenidone?
he  most  common  adverse  events  reported  for  nintedanib  in
he  TOMORROW28 and  INPULSIS  trials26 were  diarrhea,  nau-
ea,  and  vomiting,  which  were  more  prevalent  in  the  150  mg
ose  group.  Although  60%  of  patients  in  the  INPULSIS  trials
eveloped  diarrhea,  only  4%  discontinued  treatment  for  this
eason.  In  a  pooled  analysis  from  the  TOMORROW  and  INPUL-
IS  trials,  Richeldi  et  al.51 found  that  20.6%  of  patients  in
he  nintedanib  group  prematurely  discontinued  treatment
ue  to  overall  adverse  events  versus  15.0%  in  the  placebo
roup.  Nearly  30%  of  patients  in  both  groups  experienced
ne  or  more  serious  adverse  events.  Adverse  events  due  to
intedanib,  however,  are  usually  mild  or  moderate  and  can
e  easily  managed  in  most  patients.
An  interim  safety  analysis  of  the  INPULSIS-ON  extension
tudy44,45 showed  that  patients  who  completed  96  weeks
f  nintedanib  treatment  experienced  fewer  adverse  events
316.8  events  per  100  patient-years)  than  those  who  com-
leted  the  initial  52-week  evaluation  (632.6  events)  and
hose  who  initiated  treatment  after  52  weeks  on  placebo
550.6  events).  A  similar  situation  was  observed  for  seri-
us  adverse  events  (33.9  vs.  36.7  and  38.3  events  per
00  patient-years)  and  events  leading  to  treatment  discon-
inuation  (14.6  vs.  21.4  events  per  100  patient-years  in
he  other  two  groups).  The  author  concluded  that  these
nterim  results  from  the  INPULSIS-ON  trial  support  the  long-
erm  efﬁcacy  and  safety  of  nintedanib  in  patients  with
PF.
The  most  common  adverse  events  during  the  pirfenidone
APACITY19 and  ASCEND  trials25 were  gastrointestinal  events
nausea,  dyspepsia,  vomiting,  and  anorexia)  and  skin
linicalKey.com by Elsevier on October 12, 2017.
































































isorders  (rash,  photosensitivity).  The  events  were  gener-
lly  mild  or  moderate,  reversible  with  dose  reductions,  and
ithout  clinically  signiﬁcant  consequences.
In  a  comprehensive  analysis  of  safety  across  four  clinical
rials  evaluating  pirfenidone  in  patients  with  IPF,  the  more
requent  adverse  events  reported  were  also  mild  to  mod-
rate  nausea  (40%),  dyspepsia  (21%),  vomiting  (18%),  and
ash  (26%).  These  events  rarely  led  to  treatment  discontin-
ation,  despite  the  longer  median  duration  of  exposure  to
irfenidone  (2.6  years).46 This  study  also  showed  that  while
astrointestinal  and  skin-related  adverse  events  are  rela-
ively  common  at  the  beginning  of  treatment,  they  decrease
onsiderably  after  the  ﬁrst  6  months  and  remain  low  during
he  course  of  treatment.
Ogura  et  al., 41 in  a  prospective  post-marketing  surveil-
ance  study  of  patients  with  IPF  administered  pirfenidone
n  the  ﬁrst  year  after  its  launch  in  Japan,  found  a  similar
afety  proﬁle  to  that  reported  in  the  Japanese  phase  II  and
II  trials,  with  64.6%  of  patients  experiencing  at  least  one
dverse  event.  The  most  common  events  were  decreased
ppetite,  photosensitivity,  and  nausea,  and  these  resolved
r  improved  in  the  majority  of  cases.
The  results  of  the  RECAP  open-label  extension  study  of
irfenidone  showed  that  the  type  and  frequency  of  adverse
vents  after  60  weeks  of  treatment  were  similar  to  those
bserved  in  the  initial  72-week  phase  III  CAPACITY  trials
nd  rarely  resulted  in  early  discontinuation  of  therapy.43
he  incidence  of  nausea  and  photosensitivity  was  35.4%
nd  11.9%  in  the  CAPACITY  trials  versus  32.0%  and  11.8%  in
he  RECAP  study.  Rash  and  diarrhea,  by  contrast,  were  less
ommon  in  RECAP  (18.0%  and  16.9%  vs.  31.0%  and  27.0%,
espectively).21,43
onclusions
ased  on  the  available  data  from  clinical  trials  and  exten-
ion  studies,  we  can  conclude  that  both  pirfenidone  and
intedanib  have  a  signiﬁcant  effect  on  FVC  decline,  regard-
ess  of  disease  stage  assessed  by  FVC  or  GAP.  Moreover,  the
ECAP  and  INPULSIS-ON  extension  trials  showed  that  the
ffect  was  maintained  over  time.  Both  nintedanib  and  pir-
enidone  were  found  to  prolong  survival,  with  a  reduction  in
oth  IPF-related  and  all-cause  mortality.
Despite  the  relatively  high  rates  of  adverse  events,  which
re  mostly  gastrointestinal  in  nature,  the  existing  data  sup-
ort  the  recommendation  that  treatment  with  nintedanib
r  pirfenidone  should  be  considered  when  IPF  is  diagnosed,
egardless  of  disease  stage.  Since  IPF  is  a  progressive  lung
isease,  early  diagnosis  and  treatment  are  crucial  for  slow-
ng  functional  decline,  reducing  symptoms,  and  improving
uality  of  life.
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